Literature DB >> 15596409

Impaired function of circulating dendritic cells in patients with pancreatic cancer.

Hiroaki Yanagimoto1, Soichiro Takai, Sohei Satoi, Hideyoshi Toyokawa, Kanji Takahashi, Naoyoshi Terakawa, A-Hon Kwon, Yasuo Kamiyama.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: Dendritic cells (DCs) are important for immune surveillance and play a central role in protection against infection and malignancy. DCs comprise two subsets: DC1 (myeloid DC) and DC2 (lymphoid DC). The aim of this study is to determine whether the number and/or function of circulating DCs were decreased in patients with pancreatic cancer and to evaluate the effects of these changes in patients with locally advanced pancreatic cancer before and after chemoradiotherapy (CRT). We examined the circulating DC number and function using the peripheral blood from 29 patients with pancreatic cancer and 20 healthy control subjects. In patients who underwent CRT (n = 20), blood samples were taken before and after CRT. DCs were tested for the ability to stimulate allogeneic T lymphocytes in mixed leukocyte reaction (MLR). CD4/8, NK activity, PHA, and TGF-beta1 were also measured.
RESULTS: The number and allostimulatory activity of circulating DC1s in patients were significantly lower than those in controls. In the patients who underwent CRT, the allostimulatory activity of DC1s at post-CRT was significantly increased as compared to those at pre-CRT. The level of TGF-beta1 was also significantly decreased at post-CRT as compared to pre-CRT. There were no changes in CD4/8, NK activity and proliferative response of T lymphocytes at the peri-CRT period.
CONCLUSION: These data indicate that the number and function of circulating DCs were impaired in patients with pancreatic cancer. Chemoradiotherapy, however, improved DC function, which might be related to decreased immunosuppressive cytokine levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596409     DOI: 10.1016/j.clim.2004.09.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  27 in total

1.  Quantification of blood dendritic cells in colorectal cancer patients during the course of disease.

Authors:  Giulia Orsini; Annalisa Legitimo; Alessandra Failli; Paola Ferrari; Andrea Nicolini; Roberto Spisni; Paolo Miccoli; Rita Consolini
Journal:  Pathol Oncol Res       Date:  2013-09-11       Impact factor: 3.201

2.  Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation.

Authors:  Jian Du; Jingwen Wang; Guang Tan; Zhengang Cai; Lu Zhang; Bo Tang; Zhongyu Wang
Journal:  Med Oncol       Date:  2012-02-07       Impact factor: 3.064

Review 3.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 4.  Immunotherapy in pancreatic cancer treatment: a new frontier.

Authors:  Komal Thind; Leslie J Padrnos; Ramesh K Ramanathan; Mitesh J Borad
Journal:  Therap Adv Gastroenterol       Date:  2016-10-17       Impact factor: 4.409

5.  A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients.

Authors:  Runbo Zhong; Baohui Han; Hua Zhong
Journal:  Tumour Biol       Date:  2013-09-05

Review 6.  T-cell programming in pancreatic adenocarcinoma: a review.

Authors:  Y D Seo; V G Pillarisetty
Journal:  Cancer Gene Ther       Date:  2016-12-02       Impact factor: 5.987

7.  Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?

Authors:  Vegard Tjomsland; Per Sandström; Anna Spångeus; Davorka Messmer; Johan Emilsson; Ursula Falkmer; Sture Falkmer; Karl-Eric Magnusson; Kurt Borch; Marie Larsson
Journal:  BMC Cancer       Date:  2010-03-09       Impact factor: 4.430

8.  Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor.

Authors:  Vegard Tjomsland; Anna Spångeus; Per Sandström; Kurt Borch; Davorka Messmer; Marie Larsson
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

Review 9.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.

Authors:  Hans J J van der Vliet; Ruojie Wang; Simon C Yue; Henry B Koon; Steven P Balk; Mark A Exley
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.